2023–2024 COVID-19 vaccines no longer authorized, updated 2024–2025 COVID-19 vaccines now available
This message is being sent to VFC providers, VFA providers, Bridge Access Program providers, local health officers, Tribal health directors, Wisconsin vaccinators, and key DHS staff.
On August 22, 2024, the U.S. Food and Drug Administration approved the updated 2024–2025 mRNA COVID-19 vaccines. These two vaccines, manufactured by ModernaTX Inc. and Pfizer Inc., have been updated to include a monovalent (single) component that covers the Omicron variant KP.2 strain.
As a result, the 2023–2024 Moderna and Pfizer mRNA COVID-19 vaccines are no longer authorized for use and should not be administered, effective immediately. The 2023–2024 Novavax COVID-19 vaccine remains authorized but is no longer available in the United States, as all doses have expired. An updated Novavax vaccine is not yet available, but is anticipated to be approved and available in the near future.
It is critical that any remaining doses of 2023–2024 COVID-19 vaccine should be removed from storage units to ensure they are no longer administered.
For VFC providers, follow the standard return process and complete the Vaccine Return Form. Once you receive your Return ID and label, those doses should be returned to McKesson. Do not include BAP doses with this return.
BAP providers should report remaining doses as wasted in the Wisconsin Immunization Registry (WIR) to remove it from the WIR inventory and dispose of the vaccine per your facility protocol.
The updated mRNA vaccines are now available for private purchase, and the VFC and VFA program will communicate about timing and availability of these vaccines separately.
We encourage you to order these vaccines and use every opportunity to protect your patients against respiratory viruses, including COVID-19, influenza, and RSV.
|
